Incyte to Present Positive Phase 3 frontMIND Data for Tafasitamab in First-Line DLBCL at ASCO 2026
核心洞察
Incyte announced that positive Phase 3 frontMIND study results for tafasitamab in first-line diffuse large B-cell lymphoma (搜索) will be presented at the 2026 ASCO Annual Meeting.
The pivotal study evaluated tafasitamab plus lenalidomide and R-CHOP (搜索) in patients with newly diagnosed DLBCL (搜索), with results supporting global regulatory submissions.
Tafasitamab is a humanized CD19 (搜索)-targeting monoclonal antibody already approved in multiple regions for relapsed or refractory lymphomas.
Incyte announced that full results from its Phase 3 pivotal frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large B-cell lymphoma (搜索) (DLBCL (搜索)) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 – June 2, 2026, in Chicago.
The positive Phase 3 results represent a significant advancement for patients with newly diagnosed DLBCL (搜索), according to Pablo J. Cagnoni, M.D., President and Global Head of Research and Development at Incyte. "The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma (搜索) highlight Incyte's continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients," Cagnoni stated. "We look forward to sharing the full data at ASCO, and to progressing our pipeline."
Study Design and Regulatory Impact
The frontMIND study evaluated the combination of tafasitamab plus lenalidomide and R-CHOP (搜索) in patients with newly diagnosed DLBCL (搜索). The company indicated that the results support global regulatory submissions, marking a potential expansion of tafasitamab's approved indications beyond relapsed or refractory settings.
The presentation, designated as Abstract #7000, is scheduled for the Oral Abstract Session on Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia on May 30, from 4:00 – 7:00 p.m. ET.
Mechanism of Action and Current Approvals
Tafasitamab is a humanized Fc-modified cytolytic CD19 (搜索)-targeting monoclonal antibody that incorporates an XmAb® engineered Fc domain. The drug mediates B-cell lysis through apoptosis and immune effector mechanisms including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.
In the United States, Monjuvi® (tafasitamab-cxix) is approved by the FDA in combination with lenalidomide and rituximab for treating adult patients with relapsed or refractory follicular lymphoma (搜索). The drug also received accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory DLBCL (搜索) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant.
International Regulatory Status
In Europe, Minjuvi® received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for treating adult patients with relapsed or refractory DLBCL (搜索) who are not eligible for autologous stem cell transplant. In December 2025, the EMA approved Minjuvi in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (搜索) (Grade 1-3a) after at least one line of systemic therapy.
In Japan, Minjuvi is approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (搜索).
The company noted that Monjuvi is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma (搜索) outside of controlled clinical trials.
Company Portfolio and Forward-Looking Statements
Incyte describes itself as redefining biopharmaceutical innovation through deep scientific expertise and a relentless focus on patients, having built an established portfolio of first-in-class medicines across key franchises including Hematology, Oncology and Inflammation & Autoimmunity.
The company included standard forward-looking statement disclaimers, noting that statements regarding the potential and promise of tafasitamab, including its ability to provide differentiated treatment options or meaningfully impact patients with newly diagnosed DLBCL (搜索), are subject to various risks and uncertainties that may cause actual results to differ materially.